Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00849290 · ClinicalTrials.gov registry record · Phase 2

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

A Phase 2 study, sponsored by Dendreon.

Completed
Registry status
Phase 2
Development phase
113
Enrollment target

NCT00849290 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 113 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00849290, a Phase 2 study, has completed, sponsored by Dendreon.

COMPLETED
Registry status
Phase 2
Development phase
113 participants
Enrollment target

Study Summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Interventions

  • BIOLOGICAL APC8015F

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2004-04
Est. Completion 2009-04
Phase Phase 2

Sponsor

Dendreon

18 total trials

What the Registry Record Tells You About NCT00849290

The ClinicalTrials.gov registry entry for NCT00849290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which APC8015F is the first listed.

NCT00849290 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00849290 about?

NCT00849290 is a clinical study titled "Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)". This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

What is the current status of trial NCT00849290?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2004-04. Estimated completion is 2009-04.

What interventions are being tested in trial NCT00849290?

The interventions under investigation include: APC8015F (BIOLOGICAL).

Who is sponsoring clinical trial NCT00849290?

This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.